IS5183A - Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs - Google Patents

Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs

Info

Publication number
IS5183A
IS5183A IS5183A IS5183A IS5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A IS 5183 A IS5183 A IS 5183A
Authority
IS
Iceland
Prior art keywords
drug
unfinished
assessing
unprocessed
neoplastic
Prior art date
Application number
IS5183A
Other languages
English (en)
Icelandic (is)
Inventor
Niwa Kozo
Original Assignee
Niwa Kozo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niwa Kozo filed Critical Niwa Kozo
Publication of IS5183A publication Critical patent/IS5183A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS5183A 1998-09-17 1999-09-17 Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs IS5183A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (ja) 1998-09-17 1998-11-13 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法

Publications (1)

Publication Number Publication Date
IS5183A true IS5183A (is) 2000-03-17

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5183A IS5183A (is) 1998-09-17 1999-09-17 Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs

Country Status (19)

Country Link
JP (1) JP2000159682A ( )
KR (1) KR20000023206A ( )
CN (1) CN1255376A ( )
AU (1) AU4486299A ( )
BE (1) BE1012725A5 ( )
CA (1) CA2282234A1 ( )
DE (1) DE19944695A1 ( )
DK (1) DK199901235A ( )
ES (1) ES2155802B1 ( )
FR (2) FR2783426A1 ( )
GB (2) GB9920710D0 ( )
ID (1) ID23150A ( )
IL (1) IL131722A0 ( )
IS (1) IS5183A ( )
IT (1) IT1307267B1 ( )
NL (2) NL1013049C2 ( )
NO (1) NO994463L ( )
SE (2) SE9903307L ( )
SG (1) SG76631A1 ( )

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389466B1 (en) * 2001-04-27 2007-02-21 Ajinomoto Co., Inc. A dispersion on the basis of beta-glucan containing superfine particles, a corresponding process of manufacturing and the use of said dispersion
WO2002090559A1 (en) * 2001-05-07 2002-11-14 Biohub Co., Ltd. A method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
JP4499979B2 (ja) * 2001-05-21 2010-07-14 コンビ株式会社 病原菌感染抑制用組成物
JP4561098B2 (ja) * 2001-06-01 2010-10-13 味の素株式会社 糖尿病用薬剤
JP4826696B2 (ja) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 血管新生阻害剤
US7977379B2 (en) 2002-05-15 2011-07-12 Bhn Co., Ltd. Method for angiogenesis inhibition or immunostimulation
JP4681801B2 (ja) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 血管新生阻害剤およびその製造方法
JP2005089417A (ja) * 2003-09-19 2005-04-07 Noevir Co Ltd 糖尿病予防・治療用組成物
JP4587441B2 (ja) * 2004-02-12 2010-11-24 株式会社クレハ 新規な糖尿病治療剤および食品
WO2006030750A1 (ja) * 2004-09-17 2006-03-23 Ssi Co., Ltd. 乳癌を抑制するカワリハラタケ抽出物
JP2006273835A (ja) * 2005-03-04 2006-10-12 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
WO2011014729A1 (en) * 2009-07-31 2011-02-03 Yukiguni Maitake Co., Ltd. Maitake mushroom coffee
JPWO2011081024A1 (ja) * 2009-12-29 2013-05-09 株式会社富士見養蜂園 旨味食品及びその製造方法
CN106309511A (zh) * 2016-08-30 2017-01-11 青海民族大学 圆孢蘑菇抑制cdc25酶有效部位及制法和应用
CN106333969A (zh) * 2016-08-30 2017-01-18 青海民族大学 圆孢蘑菇抑制hdac1酶有效部位及制法和应用
US20200397817A1 (en) * 2017-11-30 2020-12-24 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (ko) * 2020-12-16 2024-03-12 대한민국 잎새버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102602787B1 (ko) * 2020-12-16 2023-11-17 대한민국 꽃송이버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102584680B1 (ko) * 2020-12-17 2023-10-06 대한민국 생리활성 및 영양성분이 증가된 표고버섯차 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (de) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Energetische anregung biologischer arzneimittel
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (ja) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍機能を有する食品及びその製造法
JP3357383B2 (ja) * 1991-08-14 2002-12-16 昌宏 黒田 低分子化植物性組成物
JP2955126B2 (ja) * 1992-06-22 1999-10-04 笑代 丹羽 医薬用油性製剤、食品用油性製剤およびそれらの製造方法
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
NO994463L (no) 2000-03-20
CN1255376A (zh) 2000-06-07
SE9903307L (sv) 2000-03-18
KR20000023206A (ko) 2000-04-25
ITTO990784A1 (it) 2001-03-14
NO994463D0 (no) 1999-09-15
SE9903307D0 (sv) 1999-09-16
GB2341800A (en) 2000-03-29
ES2155802B1 (es) 2001-12-01
DK199901235A (da) 2000-03-18
FR2788697A1 (fr) 2000-07-28
SE0100195L (sv) 2001-01-24
IT1307267B1 (it) 2001-10-30
NL1013049A1 (nl) 2000-03-21
AU4486299A (en) 2000-03-30
GB9920710D0 (en) 1999-11-03
DE19944695A1 (de) 2000-03-30
CA2282234A1 (en) 2000-03-17
ID23150A (id) 2000-03-23
GB9921387D0 (en) 1999-11-10
NL1019705A1 (nl) 2002-01-29
SE0100195D0 (sv) 2001-01-24
JP2000159682A (ja) 2000-06-13
BE1012725A5 (fr) 2001-02-06
ES2155802A1 (es) 2001-05-16
SG76631A1 (en) 2000-11-21
IL131722A0 (en) 2001-03-19
FR2783426A1 (fr) 2000-03-24
NL1019705C2 (nl) 2002-03-26
NL1013049C2 (nl) 2002-01-11
ITTO990784A0 (it) 1999-09-14

Similar Documents

Publication Publication Date Title
IS5183A (is) Aðferð til þess að efla æxlishemjandi virkni óunninna lyfja, blanda sem eflir æxlishemjandi virkni óunnins lyfs, aðferð til að meta æxlishemjandi skilvirkni meðhöndlunar á óunnu lyfi og aðferð til aðmeta æxlishemjandi skilvirkni óunnis lyfs
Antman et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25)
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
HK1048813A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for their use.
NO20004654L (no) Gastrobeskyttede omeprazolmikrogranuler, fremgangsmÕte for Õ oppnÕ slike og farmasøytiske preparater
NO20052410D0 (no) Vannloselige jernkarbobydratkomplekser, produksjon derav og medikamenter inneholdende disse komplekser
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
ZA200208492B (en) Game server, game machine under control of the server, and game control method.
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
CZ20022079A3 (cs) Fungicidní kombinace účinných látek, způsob hubení hub a pouľití těchto kombinací účinných látek
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
EP1471871A4 (en) TREATMENT OF NEUROLOGICAL DYSFUNCTIONS USING FRUCTOPYRANOSIS SULFAMATES AND ERYTHROPOIETIN
IS6202A (is) Lyfjauppskriftir og aðferðir til að gefa morfín ínös
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
TR199801871A3 (tr) Bifenilsulfonilsiyanamidler üretim yöntemi ve ilaç olarak kullanimlari.
ZA200309733B (en) Method and apparatus for distributing treatment agents.
DK1627631T3 (da) Morfinsulfatmikrogranuler, fremgangsmåde til fremstilling deraf og præparat omfattende samme
AP2004003070A0 (en) The method of treating cancer.
IS5809A (is) Samtíma inngjöf ACAT og MMP tálma til meðhöndlunar á skemmdum vegna fituhrörnunar